Expert Interview
Discussing the potential of Insmed's brensocatib (DPP1 inhibitor) in Chronic rhinosinusitis without nasal polyps (CRSsNP) and the ongoing Phase 2b BirCh study
Ticker(s): INSMInstitution: Northwestern University
- Chair, Department of Otolaryngology & Professor of Otolaryngology & Allergy/Immunology at Northwestern.
- Current general secretary of of ISIAN (international academic rhinologic society) and chief clinical advisor of Lyra Therapeutics.
- PI of the Clinical Core of an NIH funded Program Project Grant on Chronic Rhinosinusitis; primary clinical interests are chronic rhinosinusitis, nasal polyposis, benign and malignant sinonasal tumors and the transnasal approach for cranial base tumors.
How are CRSsNP patients managed?
Added By: wilson_adminWhere is the unmet need in CRSsNP?
Added By: wilson_adminHigh level thoughtst of brensocatib?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
